Physician profile
Del A Burchell
NPI 1619978418
$315.26
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2021: $167.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $70.75 | 2019-2021 | |
| Amgen INC. | $48.43 | 2021 | |
| Novo Nordisk INC | $42.72 | 2021 | |
| Merck Sharp & Dohme LLC | $22.06 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $20.24 | 2019 | |
| Abbott Laboratories | $19.24 | 2021 | |
| Dexcom, INC. | $17.24 | 2021 | |
| Cranial Technologies, INC | $16.50 | 2019 | |
| Allergan, INC. | $15.84 | 2019 | |
| Abbvie INC. | $15.60 | 2021 | |
| Ethicon US, LLC | $14.69 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.95 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Del Burchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.